{"url_path":"/sec/avln/13dg/2026-05-08/000089914026000428","section_key":"body","section_title":"SCHEDULE 13D body","topic":"sec","document":{"doc_type":"SCHEDULE 13D","doc_date":"2026-05-08","source_url":"https://www.sec.gov/Archives/edgar/data/1540171/0000899140-26-000428-index.html","accession_number":"0000899140-26-000428","cik":"0001540171","ticker":"AVLN","issuer_name":"Avalyn Pharma Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1540171/0000899140-26-000428-index.html","primary_entity_key":"0001540171","primary_entity_name":"Avalyn Pharma Inc."},"word_count":158,"has_tables":true,"body_markdown":"EX-1\n2\ns1050826a.htm\nJOINT FILING AGREEMENT\n\nExhibit 1\n\nJOINT FILING AGREEMENT\n\n \n\nIn accordance with Rule 13d-1(k), as promulgated under the Securities Exchange Act of 1934, as amended, the persons named below agree to\nthe joint filing on behalf of each of them a Statement on Schedule 13D (including amendments thereto) with regard to the voting common stock, $0.001 par value per share of Avalyn Pharma Inc. and further agree that this Joint Filing Agreement be\nincluded as an Exhibit to such joint filings. In evidence thereof, the undersigned, being duly authorized, hereby execute this Joint Filing Agreement as of May 8, 2026.\n\n \n\nDated: May 8, 2026\n\n \n\n \n\nAVERILL MASTER FUND, LTD.\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nBy:\n\n/s/ Andrew Nathanson\n\n \n\n \n\nName:\n\n Andrew Nathanson\n\n \n\n \n\nTitle:\n\nAuthorized Signatory\n\n \n\n \n\n \n\n \n\n \n\nAVERILL MADISON MASTER FUND, LTD.\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nBy:\n\n/s/ Andrew Nathanson\n\n \n\n \n\nName:\n\nAndrew Nathanson\n\n \n\n \n\nTitle:\n\nAuthorized Signatory\n\n \n\n \n\n \n\n \n\n \n\n \n\nSUVRETTA CAPITAL MANAGEMENT, LLC\n\n \n\n \n\n \n\n \n\n \n\n \n\nBy:\n\n/s/ Andrew Nathanson\n\n \n\n \n\nName:\n\nAndrew Nathanson\n\n \n\n \n\nTitle:\n\nGeneral Counsel and Chief Compliance Officer\n\n \n\n \n\n \n\n \n\n \n\n \n\n/s/ Aaron Cowen\n\n \n\nAaron Cowen"}